GlaxoSmithKline (GSK) Downgraded by TheStreet to C

GlaxoSmithKline (NYSE:GSK) was downgraded by equities research analysts at TheStreet from a “b-” rating to a “c” rating in a research report issued to clients and investors on Wednesday.

Several other research firms also recently issued reports on GSK. Zacks Investment Research raised shares of GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $46.00 price target on the stock in a research note on Wednesday, October 18th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a research note on Wednesday, October 18th. Bank of America downgraded shares of GlaxoSmithKline from a “buy” rating to a “neutral” rating in a research note on Thursday, October 26th. ValuEngine downgraded shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, UBS Group reaffirmed a “buy” rating on shares of GlaxoSmithKline in a research note on Monday, January 15th. Two analysts have rated the stock with a sell rating, ten have given a hold rating and six have issued a buy rating to the company. GlaxoSmithKline currently has an average rating of “Hold” and a consensus price target of $38.57.

GlaxoSmithKline (GSK) traded up $0.32 during trading on Wednesday, reaching $36.49. 5,870,919 shares of the company traded hands, compared to its average volume of 4,837,072. GlaxoSmithKline has a 12-month low of $34.52 and a 12-month high of $44.53. The stock has a market cap of $89,664.49, a P/E ratio of 46.19, a price-to-earnings-growth ratio of 2.32 and a beta of 0.98. The company has a debt-to-equity ratio of 4.09, a current ratio of 0.60 and a quick ratio of 0.44.

GlaxoSmithKline (NYSE:GSK) last released its quarterly earnings results on Wednesday, February 7th. The pharmaceutical company reported $0.72 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.69 by $0.03. GlaxoSmithKline had a net margin of 4.97% and a return on equity of 130.63%. The firm had revenue of $10.14 billion for the quarter, compared to the consensus estimate of $9.89 billion. sell-side analysts predict that GlaxoSmithKline will post 2.8 earnings per share for the current year.

Hedge funds have recently made changes to their positions in the business. FinTrust Investment Advisory Services LLC acquired a new position in GlaxoSmithKline during the 3rd quarter worth $401,000. Private Advisor Group LLC grew its holdings in GlaxoSmithKline by 7.2% during the 3rd quarter. Private Advisor Group LLC now owns 77,976 shares of the pharmaceutical company’s stock worth $3,166,000 after acquiring an additional 5,212 shares in the last quarter. San Francisco Sentry Investment Group CA grew its holdings in GlaxoSmithKline by 110.3% during the 3rd quarter. San Francisco Sentry Investment Group CA now owns 8,749 shares of the pharmaceutical company’s stock worth $356,000 after acquiring an additional 4,589 shares in the last quarter. SG Americas Securities LLC acquired a new position in GlaxoSmithKline during the 3rd quarter worth $1,209,000. Finally, Fulton Bank N.A. grew its holdings in GlaxoSmithKline by 4.9% during the 3rd quarter. Fulton Bank N.A. now owns 75,269 shares of the pharmaceutical company’s stock worth $3,056,000 after acquiring an additional 3,515 shares in the last quarter. 9.66% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This report was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.americanbankingnews.com/2018/02/10/glaxosmithkline-gsk-downgraded-by-thestreet-to-c.html.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply